Eiger BioPharmaceuticals (NASDAQ:EIGR) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a note issued to investors on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Stock Performance

The firm has a market cap of $2.55 million, a PE ratio of -0.03 and a beta of 1.83. Eiger BioPharmaceuticals has a 1 year low of $1.10 and a 1 year high of $43.35. The firm has a 50-day moving average price of $4.77 and a 200-day moving average price of $6.98.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.